Imugene Ltd Asset Resilience Ratio
Imugene Ltd asset resilience ratio. Imugene Ltd (IMU) has an Asset Resilience Ratio of 23.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See IMU defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Imugene Ltd (1995–2025)
Asset resilience ratio of Imugene Ltd from 1995 to 2025. This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. Read IMU total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see IMU total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$14.14 Million | 20.89% |
| Short-term Investments | AU$1.47 Million | 2.18% |
| Total Liquid Assets | AU$15.61 Million | 23.07% |
Asset Resilience Insights
- Good Liquidity Position: Imugene Ltd maintains a healthy 23.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imugene Ltd Industry Peers by Asset Resilience Ratio
Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Imugene Ltd Asset Resilience Ratio by Year (1995–2025)
Imugene Ltd asset resilience ratio by year from 1995 to 2025. The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 2.49% | AU$2.08 Million ≈ $1.47 Million |
AU$83.59 Million ≈ $59.14 Million |
-31.20pp |
| 2024-06-30 | 33.69% | AU$51.01 Million ≈ $36.09 Million |
AU$151.40 Million ≈ $107.12 Million |
+8.55pp |
| 2023-06-30 | 25.14% | AU$49.54 Million ≈ $35.05 Million |
AU$197.06 Million ≈ $139.43 Million |
+5.49pp |
| 2022-06-30 | 19.65% | AU$29.00 Million ≈ $20.52 Million |
AU$147.61 Million ≈ $104.44 Million |
-9.60pp |
| 2021-06-30 | 29.25% | AU$21.00 Million ≈ $14.86 Million |
AU$71.81 Million ≈ $50.81 Million |
-9.10pp |
| 2020-06-30 | 38.34% | AU$25.00 Million ≈ $17.69 Million |
AU$65.20 Million ≈ $46.14 Million |
-17.52pp |
| 2019-06-30 | 55.87% | AU$17.20 Million ≈ $12.17 Million |
AU$30.78 Million ≈ $21.78 Million |
+9.62pp |
| 2018-06-30 | 46.25% | AU$7.82 Million ≈ $5.53 Million |
AU$16.91 Million ≈ $11.97 Million |
+8.27pp |
| 2017-06-30 | 37.97% | AU$4.81 Million ≈ $3.41 Million |
AU$12.68 Million ≈ $8.97 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.54 Million ≈ $6.75 Million |
-- |
| 1996-06-30 | 4.18% | AU$387.00K ≈ $273.83K |
AU$9.25 Million ≈ $6.54 Million |
+0.33pp |
| 1995-06-30 | 3.86% | AU$460.00K ≈ $325.48K |
AU$11.93 Million ≈ $8.44 Million |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more